Senior/Staff Scientist, Chemistry at Glyphic Biotechnologies

Berkeley, California, United States

Glyphic Biotechnologies Logo
$120,000 – $183,000Compensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
BiotechnologyIndustries

Requirements

  • PhD in chemistry, organic chemistry, or related field
  • 5+ years of relevant experience in an industrial or startup setting
  • Strong background in nucleic acid & protein chemistry, bioconjugation, and analytical instrumentation
  • Comprehensive knowledge in bioconjugation and biorthogonal conjugation methods and techniques
  • Competence in peptide C-terminal conjugation chemistry
  • Experience with nucleic acid and peptide synthesis, natural and synthetic analogs
  • Experience in multi-step, small-scale organic synthesis, particularly from complex biological matrices or samples
  • Experience with HPLC, LC/MS, NMR, FTIR, UV/VIS, CE
  • Proficiency in scalable surface chemistry methods and techniques for flow cells and/or solid supports

Responsibilities

  • Design, develop, and optimize high throughput chemical reagent evaluation for single molecule protein sequencing, ensuring high sensitivity, specificity, and reproducibility
  • Synthesize assay specific reagents and materials for the proteome sequencing platform
  • Develop and/or validate peptide sample preparation schemes, such as C-terminal conjugation and amino acid sidechain derivatization
  • Collaborate with cross-functional teams to problem solve and integrate novel solutions into the assay workflow
  • Analyze complex experimental data, generate detailed reports, and provide actionable insights to guide further development
  • Utilize statistical methods and data visualization tools to interpret assay performance and ensure rigorous quality control
  • Prepare and maintain comprehensive documentation of experimental protocols, standard operating procedures (SOPs), and results
  • Drive innovation in reagent and compound synthesis and design and contribute to intellectual property development

Skills

Bioconjugation
Biorthogonal Conjugation
Peptide Synthesis
Nucleic Acid Synthesis
Organic Synthesis
HPLC
LC/MS
NMR
FTIR
UV/VIS
CE
Surface Chemistry

Glyphic Biotechnologies

Develops next-generation protein sequencing platform

About Glyphic Biotechnologies

Glyphic Biotechnologies focuses on advancing the field of proteomics by developing a unique protein sequencing platform. This platform enables researchers to analyze proteins in detail, which helps them understand biological processes and diseases better. The technology works by providing advanced sequencing services that allow for in-depth study of protein structures and functions. Unlike other companies in the biotechnology sector, Glyphic Biotechnologies emphasizes a next-generation approach to protein sequencing, aiming to deliver insights that are not available through traditional methods. The company's goal is to enhance biological and medical research by providing tools that facilitate a deeper understanding of proteins and their roles in health and disease.

New York City, New YorkHeadquarters
2021Year Founded
$41.9MTotal Funding
EARLY_VCCompany Stage
Biotechnology, HealthcareIndustries
11-50Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Unlimited Paid Time Off
Commuter Benefits
Paid Maternity and Paternity Leave
Home Office Stipend
Wellness Program
Company Equity
Employee Stock Purchase Plan

Risks

Intellectual property disputes may arise in the competitive biotechnology sector.
Dependence on external funding poses financial risks if sources become insufficient.
Rapid technological advancements may render Glyphic's platform obsolete if not updated.

Differentiation

Glyphic's platform uses single-molecule technology for precise protein sequencing.
The company accelerates protein sequencing, reducing drug development times significantly.
Glyphic's technology surpasses mass spectrometry in analyzing complex protein mixtures.

Upsides

The proteomics market is projected to grow at a CAGR of 14.7% until 2030.
Glyphic received a $409K SBIR grant from NIH for its innovative technology.
Increased interest in single-molecule protein sequencing indicates potential collaborations.

Land your dream remote job 3x faster with AI